Filing Flows › 8-K events › Health In Tech
Health In Tech: entry into a material definitive agreement
Form 8-K filed Nov 6, 2026 · items 1.01, 2.03
What the filing says
As previously disclosed, on August 12, 2026, Health In Tech, Inc. (the “Company”) entered into a Standby Equity Purchase Agreement (the “SEPA”) and a related Registration Rights Agreement. On September 4, 2026, the Company satisfied the condition set forth in the SEPA which required the Company to file with the U.S.
Read the filing on SEC EDGAR →
What usually followsAcross 23,525 8-Ks reporting Item 1.01 (material definitive agreement) in our universe, the stock's median move the next session was 0.0% (typical size ±1.4%, up 51% of the time); over the following 21 sessions, +1.0%. Item 2.03: 0.0% next session across 13,268. Every item ranked →
What this kind of filing means
Item 1.01 — Entry into a material definitive agreement. A material agreement is one the company considers important enough to disclose within four business days: a merger agreement, a large supply or customer contract, a credit agreement or a licence. The terms often move the company’s outlook more than a quarter’s results.
Item 2.03 — Creation of a direct financial obligation. New debt or a guarantee: the amount, the rate and the maturity set the cost of capital and the repayment wall ahead.
Health In Tech at a glance
Health In Tech, Q2 2026: revenue $8.1M (-14% year over year), operating margin -41.2%. The chart follows the revenue to costs, profit and cash.
Health In Tech: every quarter, Q/Q and Y/Y, holders and guidance →
Health In Tech’s other material 8-Ks
- Oct 26, 2026 — CEO changes Health In Tech Appoints Sanjay Shrestha as Chief Executive Officer to Lead Next Phase of Growth and
Other recent debt and financing
- Airsculpt Technologies Nov 6, 2026
- Starry Sea Acquisition Nov 6, 2026
- Repligen Nov 6, 2026
- Evertec Nov 6, 2026
- Clean Energy Technologies Nov 6, 2026
- Reed's Nov 6, 2026
- Protagenic Therapeutics, Inc.\new Nov 6, 2026
- CNL Strategic Residential Credit Nov 6, 2026
- Profusa Nov 6, 2026
- TuHURA Biosciences Nov 6, 2026
Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.